Kanger - Reaping benefit of COVID-19 Vaccine Distribution
As the recent news that Pfizer has announced its COVID-19 vaccine is 90% effective, indeed it is a good news for the world.
https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/
At the same time, or probably earlier, Sinopharm's vaccine also notes a great news that "None of the 56,000 people who were inoculated with a COVID-19 vaccine and traveled abroad have contracted the Coronavirus.
https://www.globaltimes.cn/content/1206008.shtml
What's similar between these two news is that:
1) Kanger is collaborating with Sinopharm on distribution of COVID-19 vaccine
https://www.theedgemarkets.com/article/kanger-collaborate-sinopharm-distribution-covid19-vaccine%C2%A0
2) Kanger inks MOU to distribute vaccine with Zuellig Pharma Sdn Bhd, who is also a distributer of Pfizer vaccine.
On Fundamental side..
- Kanger is still at the early stage of turnaround profiting company
- EPS remain at negative
- Latest financial quarter performance still not good.
- But there is hope that with the distribution chain of the vaccine, it will boost the company's earning in the long run
Technically, based on chart:
- Kanger breaks the downtrendline, eyeing for an uptrend
- If it continutes to develop higher high and higher low, you know the entry point :)
https://www.statnews.com/2020/11/09/covid-19-vaccine-from-pfizer-and-biontech-is-strongly-effective-early-data-from-large-trial-indicate/
At the same time, or probably earlier, Sinopharm's vaccine also notes a great news that "None of the 56,000 people who were inoculated with a COVID-19 vaccine and traveled abroad have contracted the Coronavirus.
https://www.globaltimes.cn/content/1206008.shtml
What's similar between these two news is that:
1) Kanger is collaborating with Sinopharm on distribution of COVID-19 vaccine
https://www.theedgemarkets.com/article/kanger-collaborate-sinopharm-distribution-covid19-vaccine%C2%A0
2) Kanger inks MOU to distribute vaccine with Zuellig Pharma Sdn Bhd, who is also a distributer of Pfizer vaccine.
On Fundamental side..
- Kanger is still at the early stage of turnaround profiting company
- EPS remain at negative
- Latest financial quarter performance still not good.
- But there is hope that with the distribution chain of the vaccine, it will boost the company's earning in the long run
Technically, based on chart:
- Kanger breaks the downtrendline, eyeing for an uptrend
- If it continutes to develop higher high and higher low, you know the entry point :)